Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which heart drug works best for seniors with multiple ailments? new trial aims to find out

NCT ID NCT05786417

Symptom relief Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study compares two common types of heart medications—beta-blockers and calcium channel blockers—in adults aged 65 and older who have stable angina (chest pain) and at least two other chronic conditions. The goal is to see which drug works better and is easier to tolerate, focusing on quality of life. About 741 participants will be followed to track how well they stick with the medication and how their symptoms change.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
beta-blocker or calcium channel blocker (anti-anginal medications)
What this could lead to
If successful, this could help doctors choose the best medication for older adults with angina and other health problems, improving quality of life and reducing side effects.
What could go wrong
This is a Phase 4 trial comparing existing drugs, so no new treatment is being discovered. Results may not apply to all patients, and individual responses to medications can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 741 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: OLDER ADULTS WITH SIHD AND MCC * Age ≥65 years * ≥ 2 Multiple Chronic Conditions as defined by Centers for Medicare and Medicaid Services (CMS) * Diagnosis of Symptomatic Stable Ischemic Heart Disease with plans to initiate medical therapy identified by at least one of the following: 1. positive non-invasive functional or anatomic testing suggestive of obstructive coronary artery disease 2. coronary angiography with stenosis ≥70% in a coronary artery ≥2 mm in diameter or ≥50% stenosis of left main 3. Invasive coronary angiography with positive physiologic testing in at least one vessel (FFR ≤ 0.80 or iFR ≤0.89) CAREGIVERS * Age ≥ 18 years * Identified as caregiver of LIVEBETTER participant Exclusion Criteria: OLDER ADULTS WITH SIHD AND MCC * Current taking (both) a beta-blocker AND a calcium channel blocker\* * Contraindication to beta-blockers or calcium channel blockers including: 1. significant hypotension 2. high grade AV block 3. severe symptomatic bradycardia 4. severe obstructive lung disease * Documented intolerance to beta-blockers or calcium channel blockers * Probable or definite high-risk coronary artery disease including unrevascularized left main disease and/or unrevascularized multi-vessel disease including the proximal left anterior descending (LAD) artery with plans for immediate complete revascularization * Plans for complete revascularization within 2 weeks * Clear clinical indication for beta-blockers or calcium channel blockers that precludes dose adjustment or crossover: 1. Diagnosis of acute coronary syndrome (ACS) with reduced ejection fraction within past year 2. Heart failure with reduced ejection fraction (HFrEF) within past year * Actively participating in another clinical trial involving an investigational medication or device * Primary language other than English or Spanish * Inability to complete follow-up (e.g. life expectancy \<12 months, impaired decision-making determined by validated instrument) * Previously enrolled in LIVEBETTER * Refused informed consent CAREGIVERS * Professional caregiver (i.e. not a relative or close friend of the participant) * Primary language other than English or Spanish * Inability to complete follow-up * Previously enrolled in LIVEBETTER * Refused informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angina are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Angina Pectoris intermediate coronary syndrome myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Angina Stable ischemic heart disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Cleveland Clinic

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

  • Cook County Health

    RECRUITING

    Chicago, Illinois, 60612, United States

  • Duke University, School of Medicine

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Inova Health Care Services

    RECRUITING

    Fairfax, Virginia, 22033, United States

  • Mt. Sinai Health System

    RECRUITING

    New York, New York, 10029, United States

  • NYC Health and Hospitals, Harlem Hospital

    NOT_YET_RECRUITING

    New York, New York, 10037-1802, United States

  • Nirvana Integrative Medicine

    RECRUITING

    New York, New York, 10469, United States

  • Wellstar Research Institute

    RECRUITING

    Marietta, Georgia, 30060, United States

  • Yale School of Medicine

    RECRUITING

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.